Skip to navigation Skip to content SciMar ONE, Inc.SciMar ONE, Inc.
Menu
  • DV Estimator
  • Our Team
  • Publications & News
Get Started
Get Started
  1. Home
  2. Posts tagged “Drug Development”

Tag: Drug Development

News

Pharmaceutical Executive Marco Taglietti, MD, Joins SciMar ONE Advisory Board

Clinical drug development expert brings 35 years of experience to SciMar’s mission to accelerate life-changing drugs to market ALLENTOWN, NJ, July 14, 2023 – SciMar ONE, Inc. (SciMar) welcomes Marco Taglietti, MD, to its Board of Advisors.  Marco is a 35-year pharmaceutical industry veteran whose career spans various clinical and executive roles with Fortune 500 and […]

July 14, 2023July 14, 2023
0
Accelerating Drug Development To Keep Pace With Drug Discovery
Publications

Forbes: Accelerating Drug Development To Keep Pace With Drug Discovery

The pharmaceutical industry invests heavily in technologies—$57.4 billion in 2022 alone—to discover new therapies to treat our greatest health challenges. Yet drug development teams are still using the same antiquated, manual processes to move those life-changing therapies toward commercialization.

March 13, 2023March 13, 2023
0
Press

MedCity News Previews 2022 HLTH Startup Competition

SciMar ONE and CEO Donna Conroy were featured by MedCity News in a preview of the healthcare startups competing at HLTH 2022.

November 30, 2022November 30, 2022
0

Sidebar

Categories

  • News
  • Press
  • Publications

Recent Posts

  • Pharmaceutical Executive Marco Taglietti, MD, Joins SciMar ONE Advisory BoardJuly 14, 2023
  • Clinical Researcher: Closing Pharma’s Financial Chasm by Measuring and Improving Development VelocityJune 21, 2023
  • NJ Tech Weekly: Woman-led SciMar ONE is all-in on New Jersey as its drug development offering evolvesMay 10, 2023

Tags

ACRP Clinical Researcher Development Velocity Drug Development Fast Company Forbes Pharma SciMar ONE

Follow us

  • SciMar on LinkedIn
  • Twitter

Follow us

  • SciMar on LinkedIn
  • Twitter

© 2022 SciMar. All rights reserved.

Top